Pediatric Radiation Oncology Clinical Research

The mission of the Pediatric Radiation Oncology Research program is to continuously improve cancer treatment and outcomes in our pediatric patients through innovative and collaborative research that we translate into clinical care.

Overview

The Francis H. Burr Proton Therapy center is actively conducting MGH lead clinical trials for pediatric cancer patients treated with Proton Therapy here at Massachusetts General Hospital. While all of these trials are led by doctors at Massachusetts General Hospital, a number of these studies enroll patients from numerous hospitals across the country adding to the cooperative nature of our research.

Currently accruing trials:

Group Members

Faculty

Torunn Yock, MD
Shannon MacDonald, MD
Nancy Tarbell, MD

Oncology Fellow

Clayton Hess, MD

Clinical Research Coordinators

Claire Goebel
Sara Gallotto
Dillon Gaudet
Megan Giblin
Jessica Nartowicz
Liz Weyman

Publications

Ladra, Matthew M., et al. "Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma." Journal of Clinical Oncology32.33 (2014): 3762-3770.

Kasper, Hallie B., et al. "The Pediatric Proton Consortium Registry: A Multi-institutional Collaboration in US Proton Centers." International Journal of Particle Therapy 1.2 (2014): 323-333.

Yock, Torunn I., et al. "Quality of life outcomes in proton and photon treated pediatric brain tumor survivors." Radiotherapy and Oncology 113.1 (2014): 89-94.

Kuhlthau, Karen A., et al. "Prospective study of health-related quality of life for children with brain tumors treated with proton radiotherapy." Journal of Clinical Oncology (2012): JCO-2011.

Houtrow, Amy J., et al. "The Family Impacts of Proton Radiation Therapy for Children With Brain Tumors." Journal of Pediatric Oncology Nursing 29.3 (2012): 171-179.

 

Research Projects

13-443 (PI: Shannon MacDonald) A Phase II Study of Proton Radiation Therapy for Neuroblastoma Tumors:   Proton radiotherapy delivers less dose to normal structures so it is therefore hypothesized that disease control will be maintained but side effects from the radiotherapy will be reduced compared with children treated with photon or X-ray based radiation.   This study aims to assess both disease control and side effects from proton radiation and includes patients with high risk neuroblastoma requiring radiotherapy. This study is Active and Enrolling.

12-103 (Torunn Yock, MD) Pediatric Proton Consortium Registry (PPCR):  This study is a multi-center registry of patients 22 years and under treated with Proton Beam Radiation Therapy (PBRT) in the United States.  The PPCR aims to describe the population that currently receives PBRT and its primary aim is to collaborate with other institutions to more quickly define the potential benefits of proton radiotherapy in the pediatric patients requiring radiotherapy.  The PPCR collects demographic and clinical data and radiation treatment plans to help facilitate research on proton radiation in children and to provide a platform and mechanism for collaborative research across institutions.  in the United States.This study is Active and Enrolling.

10-206  (PI: Torunn Yock. MD) – A Phase II Study of Proton Radiation Therapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation:  Since proton radiotherapy delivers less dose to normal structures it is hypothesized that health outcomes will be improved compared with children treated with photon or X-Ray based radiation.  This study seeks to measure disease outcomes including tumor control as well as other health outcomes such as endocrine, hearing and neurocognitive outcomes in  patients treated with proton radiotherapy. This study includes patients aged 1 year to25 years with low grade gliomas, astrocytomas, ependymomas, craniopharyngiomas, meningiomas, neurocytomas, medulloblastomas, gangliogliomas, high grade gliomas with a complete resection, or any other rare tumor requiring tumor bed or tumor irradiation.This study is Active and Enrolling.

09-361 (PI: Torunn Yock) A Phase II Trial of Proton Beam Radiation Therapy for Medulloblastoma and Pineoblastoma Tumors: An Assessment of Acute Toxicity and Long Term Neurocognitive,Neuroendocrine, and Totoxicity Outcomes:  Since proton radiotherapy delivers less dose to normal structures it is hypothesized that health outcomes will be improved compared with children treated with photon or X-Ray based radiation.  This study seeks to measure disease outcomes including tumor control as well as other health outcomes such as endocrine, hearing and neurocognitive outcomes in patients treated with proton radiotherapy. This study includes patients aged 1 year to 25 years with medulloblastoma and pineoblastoma tumors treated with proton beam radiation at Massachusetts General Hospital and at MD Anderson Cancer Center in Houston, Texas. This study is Active and Enrolling. 

09-263 (PI: Shannon MacDonald, MD) A  Phase II Study of Proton Radiation Therapy for CNS Germ Cell Tumors:  Evaluation of Acute and Late Side Effects:   Proton radiotherapy delivers less dose to normal structures so it is therefore hypothesized that disease control will be maintained but side effects from the radiotherapy will be reduced compared with children treated with photon or X-Ray based radiation.   This study aims to assess both disease control and side effects from proton radiation and includes patients aged 3 years to 25 years with germ cell tumors confined to the central nervous system.This study is Active and Enrolling.

05-326 (PI: Torunn Yock, MD) – A Phase II Study of Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas:  Proton radiotherapy delivers less dose to normal structures and therefore it is hypothesized that disease control will be maintained but side effects from the radiotherapy will be reduced compared with children treated with photon or X-Ray based radiation.   This study aims to assess both disease control and side effects from radiation and includes pediatric patients aged 1 year to 25 years with pediatric non-rhabdomyosarcoma soft tissue sarcomas and bone tumors.  Examples of common histologies of patients enrolled include Ewing’s sarcoma, synovial sarcoma, and osteosarcoma.This study is Active and Enrolling.

04-188 (PI: Torunn Yock, MD) - A Phase II Trial of Proton Radiation for the Treatment of Pediatric Rhabdomyosarcoma Tumors: Since proton radiotherapy delivers less dose to normal structures it is hypothesized that disease control will be maintained but side effects from the radiotherapy will be reduced compared with children treated with photon or X-Ray based radiation.   This study aims to assess both disease control and side effects from proton radiation and includes pediatric patients 21 years and under with newly diagnosed rhabdomyosarcoma tumors.This study is Active and Enrolling.

99-271 (Nancy Tarbell, MD) The Phase II trial, A Study of Craniospinal and Posterior Fossa Irradiation Using Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma: Assessment of Acute and Long Term Sequelae, aims to assess the short term and long term side effects of proton radiation as compared to photon radiation.  This study includes patients aged 3 years to 25 years who receive proton beam radiation for medulloblastoma or pineoblastoma tumor treatment..  Information is collected on endocrine function, hearing and neurocognitive function, brain and spine imaging, and general physical signs and symptoms to assess acute and late side effects.  This study is Closed to Accrual.

Prospective Assessment of Quality of Life (QoL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-CNS Malignancies:  This survey based study of children and their care givers examines patient and parent reported health outcomes during radiation therapy and annually thereafter.  The QoL study takes a holistic view of the child’s health and augments the clinical data collected on the phase II proton studies currently active at Massachusetts General Hospital.   This is accomplished through the PedsQL, a widely used previously validated age appropriate questionnaire, which asks both child and parent/guardian to rate their interpretation of overall well-being. This study is Active and Enrolling.

Back to Top